<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927810</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885H2251E1</org_study_id>
    <nct_id>NCT00927810</nct_id>
  </id_info>
  <brief_title>Long Term Study of Canakinumab (ACZ885) in Patients With Gout</brief_title>
  <official_title>A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This 24-week open-label extension study is designed to provide additional long-term safety&#xD;
      data up to a total of 1-year for patients rolling over from the core study, and to collect&#xD;
      further efficacy and tolerability data for all the patients, irrespective whether they have&#xD;
      an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885)&#xD;
      in this extension study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2009</start_date>
  <completion_date type="Actual">August 4, 2010</completion_date>
  <primary_completion_date type="Actual">August 4, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>From start of study up to study completion (up to 14 months)</time_frame>
    <description>Adverse events (AEs) were defined as any unfavourable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalisation, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference Change From Baseline in Participant's Gout Pain During First Flare</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Gout pain was assessed using Visual analogue scale (VAS) with a range of 0 to 100 where 0= no pain, 100= unbearable pain. Difference from time of study drug administration (pre-dose) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieved Patient's Global Assessment of Response to Treatment (5-Point Likert Scale) Based on First, Second, Third Gout Flare Category</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patient's global assessment of response to treatment is 5-point Likert scale:1.Excellent, 2.Good, 3.Acceptable, 4.Slight, 5.Poor. Lower the score better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieved Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) Based on First, Second, Third Gout Flare Category</measure>
    <time_frame>24 weeks</time_frame>
    <description>Physician's global assessment of response to treatment is 5-point Likert scale:1.Very good, 2.Good, 3.Fair, 4.Poor, 5.Very poor. Lower the score better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported No Pain, No Swelling, Absent Erythema on Physician's Assessment of Tenderness, Swelling and Erythema in Most Affected Joint During the First Flare in Participants Treated With Canakinumab by Parameter, Visit and Group</measure>
    <time_frame>24 weeks</time_frame>
    <description>Tenderness was rated on a 0-3 point scale: 0=&quot;no pain&quot;, 1=patient states that &quot;there is pain&quot;, 2=patient states &quot;there is pain and winces&quot;, and 3=patient states &quot;there is pain, winces and withdraws&quot; on palpation or passive movement of the most affected joint. Swelling was rated on a 0-3 point scale: 0=&quot;no swelling&quot;, 1=&quot;palpable&quot;, 2=&quot;visible&quot;, and 3=bulging beyond the joint margins&quot;. Erythema was rated as present, absent, or not assessable. Assessments were performed at the flare and control visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Rescue Medication After Study Drug Intake in Participants Treated With Canakinumab by Flare Order, Medication and Group</measure>
    <time_frame>24 weeks</time_frame>
    <description>The amount of naproxen and prednisolone taken after receiving treatment for each of the first 3 flares was recorded.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">341</enrollment>
  <condition>Gouty Arthritis</condition>
  <arm_group>
    <arm_group_label>canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <arm_group_label>canakinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who completed the core study CACZ885H2251. A patient is defined as completing&#xD;
             the core study if he/she completed the study up to and including the last visit (Visit&#xD;
             9).&#xD;
&#xD;
          -  Patients who have signed a written informed consent before any trial procedure is&#xD;
             performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom continuation in the extension 1 is not considered appropriate by the&#xD;
             treating physician.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive pregnancy test (serum or urine).&#xD;
&#xD;
          -  Female patients who were physiologically capable of becoming pregnant, unless they&#xD;
             were:&#xD;
&#xD;
               -  Female patients whose career, lifestyle, or sexual orientation precluded&#xD;
                  intercourse with a male partner.&#xD;
&#xD;
               -  Female patients whose partners had been sterilized by vasectomy or other means.&#xD;
&#xD;
               -  Using an acceptable method of contraception with a failure rate (Pearl Index&#xD;
                  (PI)) &lt; 1.&#xD;
&#xD;
               -  Reliable contraception had to be maintained throughout the study and for 2 months&#xD;
                  after study drug discontinuation.&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Capital Federal Buenos Aires</city>
        <zip>1027</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Bogot√°</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Praha 5</city>
        <state>Czech Republic</state>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Sachsen</city>
        <state>Dresden / Sch√ºtzenh√∂he 16</state>
        <zip>D-01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Bayern</city>
        <state>M√ºnchen / M√ºhlbaurstra√üe 16</state>
        <zip>D-81677</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Dessau</city>
        <state>Ro√ülau / K√ºhnauer Stra√üe 70 Sachsen- Anhalt</state>
        <zip>D-06846</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Debrecen</city>
        <state>Bart√≥k B U 2-26</state>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kistarcsa</city>
        <state>Semmelweis T√©r 1.</state>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Eger</city>
        <state>Sz√©chenyi U 27-29</state>
        <zip>3301</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zr√≠nyi U 1</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Pozna≈Ñ</city>
        <zip>NA 61- 734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Wroc≈Çaw</city>
        <zip>NA 50-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Lisboa</city>
        <zip>1749-004</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Singapore</city>
        <zip>169611</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Bratislava</city>
        <zip>N/A 813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Ko≈°ice</city>
        <zip>N/A 042 66</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Nitra</city>
        <zip>N/A 949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Pie≈°≈•any</city>
        <zip>N/A 921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Trenƒç√≠n</city>
        <zip>N/A 911 50</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0153</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81346</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Ankara</city>
        <state>Bahcellievler</state>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Adana</city>
        <state>Balcali</state>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>ƒ∞zmir</city>
        <state>Inciraltƒ±</state>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Aydƒ±n</city>
        <state>Merkez</state>
        <zip>09100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Manisa</city>
        <state>Merkez</state>
        <zip>45010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Gaziantep</city>
        <state>Sehitkamil</state>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Jarrow</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE32 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3.</citation>
    <PMID>21540198</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>May 13, 2021</results_first_submitted>
  <results_first_submitted_qc>May 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gouty</keyword>
  <keyword>Gouty arthritis</keyword>
  <keyword>Gout flares</keyword>
  <keyword>Anti-interleukin-1Œ≤ monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Gouty</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 75 centers in 18 countries.</recruitment_details>
      <pre_assignment_details>A total of 341 participants enrolled in the study, out of which 330 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
          <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="P2">
          <title>Core: Canakinumab, Extension: No Canakinumab</title>
          <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="P3">
          <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
          <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single SC dose of 150 mg Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="P4">
          <title>Core: Colchicine, Extension: No Canakinumab</title>
          <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]) and who did not receive canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="181"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
          <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="B2">
          <title>Core: Canakinumab, Extension: No Canakinumab</title>
          <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="B3">
          <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
          <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="B4">
          <title>Core: Colchicine, Extension: No Canakinumab</title>
          <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="60"/>
            <count group_id="B5" value="341"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="10.20"/>
                    <measurement group_id="B2" value="53.8" spread="11.39"/>
                    <measurement group_id="B3" value="52.0" spread="11.00"/>
                    <measurement group_id="B4" value="51.5" spread="9.45"/>
                    <measurement group_id="B5" value="52.6" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>Adverse events (AEs) were defined as any unfavourable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalisation, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards</description>
        <time_frame>From start of study up to study completion (up to 14 months)</time_frame>
        <population>Safety Set 1 consisted of all participants from the core study who entered the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O2">
            <title>Core: Canakinumab, Extension: No Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O3">
            <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O4">
            <title>Core: Colchicine, Extension: No Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>Adverse events (AEs) were defined as any unfavourable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalisation, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards</description>
          <population>Safety Set 1 consisted of all participants from the core study who entered the extension study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Change From Baseline in Participant's Gout Pain During First Flare</title>
        <description>Gout pain was assessed using Visual analogue scale (VAS) with a range of 0 to 100 where 0= no pain, 100= unbearable pain. Difference from time of study drug administration (pre-dose) was reported.</description>
        <time_frame>Baseline and Day 7</time_frame>
        <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O2">
            <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Change From Baseline in Participant's Gout Pain During First Flare</title>
          <description>Gout pain was assessed using Visual analogue scale (VAS) with a range of 0 to 100 where 0= no pain, 100= unbearable pain. Difference from time of study drug administration (pre-dose) was reported.</description>
          <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.7" spread="15.86"/>
                    <measurement group_id="O2" value="-67.4" spread="21.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieved Patient's Global Assessment of Response to Treatment (5-Point Likert Scale) Based on First, Second, Third Gout Flare Category</title>
        <description>Patient's global assessment of response to treatment is 5-point Likert scale:1.Excellent, 2.Good, 3.Acceptable, 4.Slight, 5.Poor. Lower the score better the outcome.</description>
        <time_frame>24 weeks</time_frame>
        <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O2">
            <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieved Patient's Global Assessment of Response to Treatment (5-Point Likert Scale) Based on First, Second, Third Gout Flare Category</title>
          <description>Patient's global assessment of response to treatment is 5-point Likert scale:1.Excellent, 2.Good, 3.Acceptable, 4.Slight, 5.Poor. Lower the score better the outcome.</description>
          <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1. Gout Flare: Excellent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Acceptable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Slight</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Excellent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Acceptable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Slight</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Excellent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Acceptable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Slight</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieved Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) Based on First, Second, Third Gout Flare Category</title>
        <description>Physician's global assessment of response to treatment is 5-point Likert scale:1.Very good, 2.Good, 3.Fair, 4.Poor, 5.Very poor. Lower the score better the outcome.</description>
        <time_frame>24 weeks</time_frame>
        <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O2">
            <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieved Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) Based on First, Second, Third Gout Flare Category</title>
          <description>Physician's global assessment of response to treatment is 5-point Likert scale:1.Very good, 2.Good, 3.Fair, 4.Poor, 5.Very poor. Lower the score better the outcome.</description>
          <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1. Gout Flare: Very Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Fair</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Gout Flare: Very Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Very good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Fair</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2. Gout Flare: Very poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Very Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Fair</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Gout Flare: Very poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported No Pain, No Swelling, Absent Erythema on Physician's Assessment of Tenderness, Swelling and Erythema in Most Affected Joint During the First Flare in Participants Treated With Canakinumab by Parameter, Visit and Group</title>
        <description>Tenderness was rated on a 0-3 point scale: 0=&quot;no pain&quot;, 1=patient states that &quot;there is pain&quot;, 2=patient states &quot;there is pain and winces&quot;, and 3=patient states &quot;there is pain, winces and withdraws&quot; on palpation or passive movement of the most affected joint. Swelling was rated on a 0-3 point scale: 0=&quot;no swelling&quot;, 1=&quot;palpable&quot;, 2=&quot;visible&quot;, and 3=bulging beyond the joint margins&quot;. Erythema was rated as present, absent, or not assessable. Assessments were performed at the flare and control visits.</description>
        <time_frame>24 weeks</time_frame>
        <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O2">
            <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported No Pain, No Swelling, Absent Erythema on Physician's Assessment of Tenderness, Swelling and Erythema in Most Affected Joint During the First Flare in Participants Treated With Canakinumab by Parameter, Visit and Group</title>
          <description>Tenderness was rated on a 0-3 point scale: 0=&quot;no pain&quot;, 1=patient states that &quot;there is pain&quot;, 2=patient states &quot;there is pain and winces&quot;, and 3=patient states &quot;there is pain, winces and withdraws&quot; on palpation or passive movement of the most affected joint. Swelling was rated on a 0-3 point scale: 0=&quot;no swelling&quot;, 1=&quot;palpable&quot;, 2=&quot;visible&quot;, and 3=bulging beyond the joint margins&quot;. Erythema was rated as present, absent, or not assessable. Assessments were performed at the flare and control visits.</description>
          <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness-Flare Visit- No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness-Control Visit- No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint swelling-Flare Visit-No swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint swelling-Control Visit-No swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema-Flare Visit-Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema-Control Visit-Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Rescue Medication After Study Drug Intake in Participants Treated With Canakinumab by Flare Order, Medication and Group</title>
        <description>The amount of naproxen and prednisolone taken after receiving treatment for each of the first 3 flares was recorded.</description>
        <time_frame>24 weeks</time_frame>
        <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
          <group group_id="O2">
            <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
            <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Rescue Medication After Study Drug Intake in Participants Treated With Canakinumab by Flare Order, Medication and Group</title>
          <description>The amount of naproxen and prednisolone taken after receiving treatment for each of the first 3 flares was recorded.</description>
          <population>Efficacy Set consisted of all participants who received at least one dose of canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]. Here the number of participants analyzed signifies participants who were evaluable for this measure.</population>
          <units>milligrams (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.Gout flare-Naproxen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1086.8" spread="1592.72"/>
                    <measurement group_id="O2" value="954.6" spread="1130.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.Gout flare-Prednisolone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="20.84"/>
                    <measurement group_id="O2" value="4.2" spread="20.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.Gout flare-Naproxen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.0" spread="642.79"/>
                    <measurement group_id="O2" value="200.0" spread="447.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.Gout flare-Prednisolone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.11"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.Gout flare-Naproxen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.0" spread="500.00"/>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.Gout flare-Prednisolone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study up to study completion (up to 14 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Core: Canakinumab 25 mg</title>
          <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Core: Canakinumab 50 mg</title>
          <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Core: Canakinumab 100 mg</title>
          <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Core: Canakinumab 200 mg</title>
          <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Core: Canakinumab 300 mg</title>
          <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Core : Canakinumab Q4wk mg</title>
          <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Core : Colchicine 0.5 mg</title>
          <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
        </group>
        <group group_id="E8">
          <title>Core: Canakinumab, Extension: 150 mg Canakinumab</title>
          <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="E9">
          <title>Core: Canakinumab, Extension: No Canakinumab</title>
          <description>Participants who were randomized to canakinumab in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="E10">
          <title>Core: Colchicine, Extension: 150 mg Canakinumab</title>
          <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]), received single subcutaneous (SC) dose of 150 milligrams (mg) Canakinumab (ACZ885) for at least one flare in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
        <group group_id="E11">
          <title>Core: Colchicine, Extension: No Canakinumab</title>
          <description>Participants who were randomized to colchicine in the core study (NCT00819585 [CACZ885H2251]) and who did not received canakinumab in this extension study (NCT00927810 [CACZ885H2251E1]).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

